11.79
+0.1(+0.86%)
Currency In USD
| Previous Close | 11.69 |
| Open | 11.69 |
| Day High | 11.96 |
| Day Low | 11.58 |
| 52-Week High | 15.11 |
| 52-Week Low | 5.45 |
| Volume | 98,311 |
| Average Volume | 232,201 |
| Market Cap | 386.15M |
| PE | -12.68 |
| EPS | -0.93 |
| Moving Average 50 Days | 11.76 |
| Moving Average 200 Days | 9.78 |
| Change | 0.1 |
If you invested $1000 in NeuroPace, Inc. (NPCE) since IPO date, it would be worth $472.36 as of May 02, 2025 at a share price of $11.79. Whereas If you bought $1000 worth of NeuroPace, Inc. (NPCE) shares 3 years ago, it would be worth $1,635.23 as of May 02, 2025 at a share price of $11.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NeuroPace Provides Update on Tariff Status
GlobeNewswire Inc.
Apr 14, 2025 8:05 PM GMT
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical devic
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
NeuroPace RNS System NeuroPace RNS System Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term seizure reduction with a median reduction of 82% at
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
GlobeNewswire Inc.
Apr 03, 2025 12:00 PM GMT
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device com